Histology and fine structure of the iris and outflow system following latanoprost therapy

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Grierson, Ian ^a,c   Pfeiffer, Norbert ^b   Cracknell, Kathryn P B ^a   Appleton, Paul ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Clinical Department   (United Kingdom)

Author keywords

Eye color change; Iris; Latanoprost; Melanin; Morphology; Outflow system

Indexed keywords

LATANOPROST; MELANIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR;

AQUEOUS HUMOR FLOW; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFECT; ELECTRON MICROSCOPY; EYE COLOR; GLAUCOMA; HUMAN; HYPERPIGMENTATION; INTRAOCULAR PRESSURE; IRIS; MELANOCYTE; MELANOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRABECULECTOMY;

EID: 0036669751     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00304-1     Document Type: Article

References (29)

1. Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res. 17:1998;291-312.
2. Alm A., Camaras C., Watson P. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 41(Suppl 2):1997;S105-S110.
3. Bito L.Z. Prostaglandins. a new approach to glaucoma management with a new, intriguing side effect Surv Ophthalmol. 41(Suppl 2):1997;S1-S14.
4. Broekhuyse R.M., Kuhlmann E.D. Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin. Invest Ophthalmol Vis Sci. 34:1993;698-700.
5. Campbell D.G. Pigmentary dispersion and glaucoma. A new theory. Arch Ophthalmol. 97:1979;1667-1672.
6. Chowers I., Livni N., Solomon A.et al. MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia. Br J Ophthalmol. 82:1998;1316-1319.
7. Drago F., Marino A., La Manna C. alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res. 68:1999;85-90.
8. Eagle R.C. Jr. Iris pigmentation and pigmented lesions. an ultrastructural study Trans Am Ophthalmol Soc. 86:1988;581-687.
9. Farrar S.M., Shields M.B. Current concepts in pigmentary glaucoma. Surv Ophthalmol. 37:1993;233-252.
10. Freddo T.F. Ultrastructure of the iris. Microsc Res Tech. 33:1996;369-389.
11. Grierson I., Cracknell K.P., Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol. 12:2001;112-118.
12. Grierson I., Hogg P. The proliferative and migratory activities of trabecular meshwork cells. Prog Retin Eye Res. 15:1995;3367.
13. Grierson I. What is open angle glaucoma? Eye. 1:1987;15-28.
14. Grierson I., Lee W.R., Albert D.M. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol. 117:1999;394-396.
15. Grierson I., Pfeiffer N. The morphology of irides treated with latanoprost. Diestelhorst M. Prostaglandins in Ophthalmology. 1998;105-110 Germany, Kaden Verlag, Heidelberg.
16. Hogan M., Alvarado J., Weddell J. Histology of the Human Eye. An Atlas and Textbook:1971;WB Saunders, Philadelphia.
17. Hu D.N., Stjernschantz J., McCormick S.A. Effect of prostaglandins A(2), E(1), F(2 alpha)and latanoprost on cultured human iridal melanocytes. Exp Eye Res. 70:2000;113-120.
18. Imesch P.D., Bindley C.D., Khademian Z.et al. Melanocytes and iris color. Electron microscopic findings. Arch Ophthalmol. 114:1996;443-447.
19. Lee W.R. The pathology of the outflow system in primary and secondary glaucoma. Eye. 9:1995;1-23.
20. Lindquist N.G., Larsson B.S., Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res. 68:1999;431-436.
21. Loeffler K.U., Sahm M. Latanoprost and melanogenesis in porcine iris cells. Proc Int Soc Eye Res. 14:2000;53. [abstract].
22. Pfeiffer N., Grierson I., Goldsmith H.et al. Histological effects in the iris after 3 months of latanoprost therapy. the Mainz 1 study Arch Ophthalmol. 119:2001;191-196.
23. Prota G., Vincensi M.R., Napolitano A.et al. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 13:2000;147-150.
24. Selen G., Stjernschantz J., Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 41(Suppl 2):1997;S125-S128.
25. Siegfried C.J., Hendricks R.L. Melanin can deplete immunosuppressive substances from the aqueous humor. Curr Eye Res. 13:1994;869-873.
26. Stjernschantz J. Significance and time-course of prostaglandin-induced increase in iridial pigmentation in primates and man. Diestelhorst M. Prostaglandins in Opthalmology. 1998;111-116 Germany, Kaden Verlag, Heidelberg.
27. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 103:1996;126-137.
28. Wilkerson C.L., Syed N.A., Fisher M.R.et al. Melanocytes and iris color. Light microscopic findings. Arch Ophthalmol. 114:1996;437-442.
29. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 41(Suppl 2):1997;S129-S138.